Zacks Investment Research downgraded shares of MIRATI THERAPTC (MRTX) from OUTPERFORM to NEUTRAL on September 23, 2013, with a target price of $17.10.
Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on MIRATI THERAPTC (MRTX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment